Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II study of TP/TPF short induction chemotherapy and radiotherapy with or without cetuximab for laryngectomy-only operable laryngeal/hypopharyngeal carcinoma
2006-006091-38Phase 2Completed
- Sponsor
- Leipzig University
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of cetuximab in laryngeal squamous cell carcinoma (LSCC) and squamous cell carcinoma of the hypopharynx (2 arms), sponsored by Leipzig University. Primary endpoints: Tumor reduction threshold for study continuation and Two-year survival with functional larynx preservation. Started Apr 2007; status: completed.
02
Drugs
cetuximab
03
Conditions
laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on 2006-006091-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006091-38.